托珠单抗对成年类风湿关节炎患者中性粒细胞的影响:3期和4期临床试验数据的汇总分析
该汇总分析纳入接受静脉托珠单抗或安慰剂治疗的类风湿关节炎患者,发现托珠单抗组中性粒细胞计数降低更常见,但严重感染率在正常与降低的中性粒细胞计数间相似,且当前风险缓解指南可使中性粒细胞计数正常化。
要点
- 托珠单抗治疗者中性粒细胞计数降低更常见,但严重感染率与中性粒细胞计数水平无明显关联。
- 基线中性粒细胞计数<2×10^9/l和女性与3/4级中性粒细胞减少相关。
- 因中性粒细胞降低而停用托珠单抗者较减量或继续用药者恢复更快。
核心结论
- 托珠单抗治疗所致中性粒细胞计数降低似乎与严重感染无关,且当前风险缓解指南可使中性粒细胞计数正常化。
研究设计与样本
- 汇总3/4期临床试验、长期扩展或药理学研究中接受静脉托珠单抗(4 mg/kg+MTX、8 mg/kg±DMARDs、10 mg/kg)或安慰剂+DMARDs的类风湿关节炎患者数据。
主要发现
- 在安慰剂对照部分,托珠单抗组1/2级或3/4级中性粒细胞计数发生率分别为28.2%和3.1%,安慰剂组分别为8.9%和0.2%。
- 在安慰剂对照试验+长期扩展中,4171例患者提供16204.8患者年的托珠单抗暴露。
- 中性粒细胞计数从基线至第6周下降[平均(s.d.)变化,-2.17(2.16)×10^9/l],此后保持稳定。
- 正常、1/2级和3/4级中性粒细胞计数后30天内严重感染率(95%CI)分别为4.66(4.31, 5.03)、2.48(1.79, 3.34)和2.77(0.34, 10.01)/100患者年。
- 基线中性粒细胞计数<2×10^9/l和女性与3/4级中性粒细胞计数相关[OR(95%CI):19.02(6.76, 53.52)、2.55(1.40, 4.66)]。
关键数值与推荐
- 中性粒细胞计数按常见不良事件毒性标准分级,必要时调整托珠单抗剂量。
临床怎么用
- 临床中托珠单抗治疗期间中性粒细胞计数降低常见,但严重感染风险未明显增加,可按风险缓解指南管理。
- 对基线中性粒细胞计数<2×10^9/l或女性患者应关注3/4级中性粒细胞减少风险。
- 若出现中性粒细胞计数降低,停药可能比减量或继续用药更快恢复至正常水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate changes in neutrophil count and occurrences of infection in RA patients treated with the IL-6 receptor-α inhibitor tocilizumab (TCZ). METHODS: Data were pooled from patients who received i.v. TCZ (4 mg/kg + MTX, 8 mg/kg ± DMARDs, 10 mg/kg) or placebo + DMARDs in phase 3/4 clinical trials, long-term extensions or a pharmacology study. Neutrophil counts were measured routinely according to the Common Toxicity Criteria for Adverse Events grades; TCZ dosing was adjusted if necessary. Covariates associated with decreased neutrophil counts were assessed with multivariate regression analysis. Infection rates within 30 days of neutrophil count changes were calculated per 100 patient-years of TCZ exposure. RESULTS: In placebo-controlled parts of trials, more TCZ-treated than placebo-treated patients had grade 1/2 or 3/4 neutrophil counts (TCZ: 28.2%/3.1%; placebo: 8.9%/0.2%). In placebo-controlled trials + long-term extensions, 4171 patients provided 16204.8 patient-years of TCZ exposure. Neutrophil counts decreased through week 6 from baseline [mean ( s . d .) change, -2.17 (2.16) × 10 9 /l) and remained stable thereafter. Rates (95% CI) of serious infections within 30 days of normal [4.66 (4.31, 5.03)], grade 1/2 [2.48 (1.79, 3.34)] and 3/4 [2.77 (0.34, 10.01)] neutrophil counts were similar. Baseline neutrophil count <2 × 10 9 /l and female gender were associated with grade 3/4 neutrophil counts [odds ratio (OR) (95% CI): 19.02 (6.76, 53.52), 2.55 (1.40, 4.66)]. Patients who stopped TCZ in response to decreased neutrophil count returned more quickly to normal levels than patients who reduced or continued their dose. CONCLUSION: Decreases in neutrophil counts in patients taking TCZ do not appear to be associated with serious infections and are normalized by current risk mitigation guidelines.
引用
- Moots RJ, Sebba A, Rigby W, et al. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. Rheumatology (Oxford). 2017. PMID: 28013198. doi:10.1093/rheumatology/kew370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。